title: The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
abstract: Current treatment strategies in patients with newly-diagnosed glioblastoma include surgical resection with post-operative radiotherapy and concomitant/adjuvant temozolomide (the "Stupp protocol") or resection with implantation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafers in the surgical cavity followed by radiotherapy. In clinical practice, patients with malignant glioma treated with BCNU wafer often also receive adjuvant temozolomide. However, current treatment guidelines are unclear on whether and how these treatment practices can be combined, and no prospective phase 3 study has assessed the safety and efficacy of combining BCNU wafers with temozolomide and radiation in high-grade malignant glioma. The rationale for multimodal therapy comprising surgical resection with adjunct local BCNU wafers followed by radiotherapy and temozolomide is based on complementary and synergistic mechanisms of action between BCNU and temozolomide in preclinical studies; a shared primary resistance pathway, methylguanine-DNA methyltransferase (MGMT); and the opportunity to overcome resistance through MGMT depletion to boost cytotoxic activity. A comprehensive review of the literature identified 19 retrospective and prospective studies investigating the use of this multimodal strategy. Median overall survival in 14 studies of newly-diagnosed patients suggested a modest improvement versus resection followed by Stupp protocol or resection with BCNU wafers, with an acceptable and manageable safety profile.
authors.affiliation: Department of Neurosurgery, University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Gutenberg
authors.forename: C B
authors.initials: CB
authors.lastname: Lumenta
authors.forename: W E K
authors.initials: WE
authors.lastname: Braunsdorf
authors.forename: M
authors.initials: M
authors.lastname: Sabel
authors.forename: H M
authors.initials: HM
authors.lastname: Mehdorn
authors.forename: M
authors.initials: M
authors.lastname: Westphal
authors.forename: A
authors.initials: A
authors.lastname: Giese
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D011379:Prognosis; D000077204:Temozolomide
chemical_list: D003606:Dacarbazine; D002330:Carmustine; D000077204:Temozolomide
references.citation: Lancet Oncol. 2006 May;7(5):392-401
references.pmid: 16648043
references.citation: Neuro Oncol. 2001 Oct;3(4):246-50
references.pmid: 11584894
references.citation: Neuro Oncol. 2009 Feb;11(1):69-79
references.pmid: 18772354
references.citation: Neuro Oncol. 2003 Apr;5(2):79-88
references.pmid: 12672279
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v190-3
references.pmid: 20555079
references.citation: Cancer Res. 1994 Jul 15;54(14):3793-9
references.pmid: 8033099
references.citation: Mol Cancer. 2011 Oct 11;10:128
references.pmid: 21988793
references.citation: J Neurosurg Sci. 2011 Mar;55(1):1-6
references.pmid: 21464805
references.citation: Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9
references.pmid: 9218294
references.citation: J Neurooncol. 2012 Jul;108(3):521-5
references.pmid: 22467191
references.citation: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD007415
references.pmid: 18843749
references.citation: Neuro Oncol. 2012 Apr;14(4):482-90
references.pmid: 22319220
references.citation: Neurology. 2011 Jan 4;76(1):87-93
references.pmid: 21205697
references.citation: N Engl J Med. 1980 Dec 4;303(23):1323-9
references.pmid: 7001230
references.citation: Cancer Control. 1998 Mar;5(2):130-137
references.pmid: 10761024
references.citation: Clin Neurol Neurosurg. 2012 Nov;114(9):1222-5
references.pmid: 22464950
references.citation: Oncogene. 2007 Jan 11;26(2):186-97
references.pmid: 16819506
references.citation: Surg Neurol. 2007 Oct;68(4):412-20; discussion 420
references.pmid: 17905066
references.citation: Curr Med Res Opin. 2008 Nov;24(11):3239-57
references.pmid: 18940042
references.citation: J Clin Neurosci. 2011 Mar;18(3):347-51
references.pmid: 21237660
references.citation: Cancer Res. 1987 Aug 1;47(15):3988-94
references.pmid: 3038305
references.citation: N Engl J Med. 2000 Nov 9;343(19):1350-4
references.pmid: 11070098
references.citation: Cancer. 2009 Aug 1;115(15):3501-11
references.pmid: 19514083
references.citation: Acta Neurochir (Wien). 2007 Mar;149(3):261-5; discussion 265
references.pmid: 17334672
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: Cancer. 2012 Sep 15;118(18):4545-54
references.pmid: 22359215
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1257-61
references.pmid: 19188676
references.citation: Lancet Oncol. 2009 May;10(5):459-66
references.pmid: 19269895
references.citation: Neurosurg Rev. 2010 Oct;33(4):441-9
references.pmid: 20706757
references.citation: Expert Opin Drug Saf. 2009 Jul;8(4):493-9
references.pmid: 19435405
references.citation: Cent Eur Neurosurg. 2010 Nov;71(4):199-206
references.pmid: 20063259
references.citation: J Neurosurg. 2009 Mar;110(3):583-8
references.pmid: 19046047
references.citation: J Neurochem. 2012 Jul;122(2):444-55
references.pmid: 22564186
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1262-7
references.pmid: 19204199
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):1064-8
references.pmid: 19188181
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):328-31
references.pmid: 16428468
references.citation: J Neurosurg. 2002 May;96(5):941-5
references.pmid: 12005403
references.citation: Ann Surg Oncol. 2010 Jul;17(7):1740-6
references.pmid: 20443147
references.citation: Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):749-55
references.pmid: 21300471
references.citation: Acta Neurochir (Wien). 2011 Jun;153(6):1211-8
references.pmid: 21479583
references.citation: Cancer Res. 2007 Dec 15;67(24):11886-95
references.pmid: 18089819
references.citation: Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275
references.pmid: 16482400
references.citation: Neurology. 2004 Oct 12;63(7):1281-4
references.pmid: 15477552
references.citation: Clin Pharmacokinet. 2002;41(6):403-19
references.pmid: 12074689
references.citation: Clin Cancer Res. 2008 May 15;14(10):2900-8
references.pmid: 18483356
references.citation: Lancet. 1995 Apr 22;345(8956):1008-12
references.pmid: 7723496
references.citation: Surg Neurol. 2000 Mar;53(3):220-4
references.pmid: 10773252
references.citation: Cancer. 1983 Sep 15;52(6):997-1007
references.pmid: 6349785
references.citation: Br J Cancer. 2000 Sep;83(5):588-93
references.pmid: 10944597
references.citation: Cancer. 2009 Oct 15;115(20):4783-94
references.pmid: 19637364
references.citation: Clin Cancer Res. 2002 Aug;8(8):2725-34
references.pmid: 12171906
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Neuro Oncol. 2004 Jan;6(1):33-7
references.pmid: 14769138
references.citation: J Neurooncol. 2008 Jul;88(3):353-7
references.pmid: 18389176
references.citation: Cancer. 2004 Apr 15;100(8):1712-6
references.pmid: 15073861